Metabolic disorders associated with the use of targeted cancer therapies

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Targeted therapies represent a significant advancement in cancer treatment, differing mechanistically from traditional cytotoxic agents.
• The increasing use of these novel therapies has led to the emergence of previously unrecognized toxicities, particularly metabolic disorders.
• There is a need to understand the incidence and underlying mechanisms of these therapy-induced metabolic dysregulations.

Purpose of the Study:

• To conduct a systematic literature review on the incidence and physiopathology of metabolic disorders induced by targeted therapies.
• To provide guidance on the management of these emerging adverse events.
• To raise awareness among medical oncologists regarding these potential toxicities.

Main Methods:

• Systematic literature review.
• Analysis of incidence and physiopathology data.
• Development of management recommendations.

Main Results:

• Targeted therapies and immunotherapies are associated with metabolic toxicities including endocrine disorders, dyslipidemia, induced diabetes, and electrolyte imbalances.
• These metabolic disorders are becoming more prevalent with the use of targeted agents.
• While increasingly common, these disorders are typically not life-threatening and are often reversible with timely intervention.

Conclusions:

• Medical oncologists must be aware of the symptoms of targeted therapy-induced metabolic disorders.
• Close patient monitoring for these side effects is crucial.
• Collaborative management involving endocrinologists and other specialists is essential for optimal patient care.